论文部分内容阅读
目的分析美托洛尔联合曲美他嗪治疗冠心病心力衰竭的临床效果。方法 80例冠心病心力衰竭患者,使用随机数字表将患者分为对照组和观察组,各40例,两组患者均予以常规治疗,观察组同时使用美托洛尔联合曲美他嗪治疗,对比两组患者的治疗结果。结果观察组治疗总有效率为95.0%,高于对照组的75.0%,差异具有统计学意义(χ~2=6.275,P<0.05)。治疗前,两组患者的左室射血分数(LVEF)、左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、6 min步行距比较,差异均无统计学意义(t=0.877、0.842、0.192、0.174,P>0.05)。治疗后,观察组与对照组的上述指标均有所改善,且观察组优于对照组,差异均具有统计学意义(t=5.547、9.087、7.057、4.403,P<0.05)。结论应用美托洛尔联合曲美他嗪治疗冠心病心力衰竭能够更好的改善患者的心功能,从而提高治疗效果,值得在临床推广。
Objective To analyze the clinical effect of metoprolol combined with trimetazidine in the treatment of heart failure with coronary heart disease. Methods Eighty patients with heart failure of coronary heart disease were divided into control group and observation group using random number table, 40 cases in each group. Both groups were treated by metoprolol combined with metoprolol and trimetazidine. The results of the two groups of patients were compared. Results The total effective rate of observation group was 95.0%, which was higher than that of the control group (75.0%), the difference was statistically significant (χ ~ 2 = 6.275, P <0.05). Before treatment, LVEF, LVESD, LVEDD and 6-min walking distance between the two groups had no significant difference (t = 0.877 , 0.842,0.192,0.174, P> 0.05). After treatment, the above indexes in observation group and control group all improved, and the observation group was superior to the control group, the differences were statistically significant (t = 5.547,9.087,7.057,4.403, P <0.05). Conclusion The application of metoprolol combined with trimetazidine in patients with coronary heart disease and heart failure can better improve the patient’s cardiac function, thereby enhancing the therapeutic effect, which is worthy of clinical promotion.